Attitudes and Perceptions Toward Authorized Deception: A Pilot Comparison of Healthy Controls and Fibromyalgia Patients
Date
2020Journal
Pain medicine (Malden, Mass.)Publisher
Oxford University PressType
Article
Metadata
Show full item recordAbstract
Objective: Little is known about the perceptions and attitudes of participants who volunteer in studies involving authorized deception. Thus, this cross-sectional pilot study measured, for the first time, the perceptions about participation in an authorized-deception placebo analgesia study in chronic pain patients with fibromyalgia and assessed whether their perceptions differed from healthy controls. Methods: An anonymous survey with questions about trust in research and willingness to participate in future research involving deception was mailed to participants in both groups after completion of the parent study. Statistical analyses were performed using the Mann-Whitney U and chi-square tests (31 controls and 16 fibromyalgia patients were included in the analyses). Results: The majority of participants expressed little or no concern about the deception, still trusted the scientific process, and found the debriefing procedure helpful and worthwhile. Group differences were found in willingness to 1) participate in the parent study had the deceptive element been disclosed in advance (controls = definitely, fibromyalgia patients = probably, U = 341.5, P = 0.01) and 2) participate in future studies (controls = definitely, fibromyalgia patients = probably, U = 373, P < 0.001). Conclusions: Despite slightly less favorable responses of fibromyalgia patients and the relatively small size of the study, these findings suggest that attitudes and perceptions about participating in an authorized placebo study remain positive in both healthy and chronic pain populations.Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083003316&doi=10.1093%2fpm%2fpnz081&partnerID=40&md5=e3f7093a626c502c80c6241c960eda18; http://hdl.handle.net/10713/12610ae974a485f413a2113503eed53cd6c53
10.1093/pm/pnz081
Scopus Count
Collections
Related articles
- Inclusion of authorized deception in the informed consent process does not affect the magnitude of the placebo effect for experimentally induced pain.
- Authors: Martin AL, Katz J
- Issue date: 2010 May
- A Comparison of Deceptive and Non-Deceptive Placebo Analgesia: Efficacy and Ethical Consequences.
- Authors: Mundt JM, Roditi D, Robinson ME
- Issue date: 2017 Apr
- Lower Placebo Responses After Long-Term Exposure to Fibromyalgia Pain.
- Authors: Kosek E, Rosen A, Carville S, Choy E, Gracely RH, Marcus H, Petzke F, Ingvar M, Jensen KB
- Issue date: 2017 Jul
- Placebo use in pain management: The role of medical context, treatment efficacy, and deception in determining placebo acceptability.
- Authors: Kisaalita N, Staud R, Hurley R, Robinson M
- Issue date: 2014 Dec
- Endogenous pain modulation in response to exercise in patients with rheumatoid arthritis, patients with chronic fatigue syndrome and comorbid fibromyalgia, and healthy controls: a double-blind randomized controlled trial.
- Authors: Meeus M, Hermans L, Ickmans K, Struyf F, Van Cauwenbergh D, Bronckaerts L, De Clerck LS, Moorken G, Hans G, Grosemans S, Nijs J
- Issue date: 2015 Feb